Kiora Pharmaceuticals, Inc. filed its 10-K on Mar 23, 2023 for the period ending Dec 31, 2022. In this report its auditor, EisnerAmper LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4862 USD | +0.19% | -5.28% | -6.93% |
May. 10 | Earnings Flash (KPRX) KIORA PHARMACEUTICALS Posts Q1 Revenue $16M | MT |
Mar. 25 | Kiora Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.93% | 12.77M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- KPRX Stock
- News Kiora Pharmaceuticals, Inc.
- Kiora Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt